

Adult CIRB - Early Phase Emphasis Meeting Agenda

February 4, 2020

I Continuing Review

10061, A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (Protocol Version Date 06/07/19)

II Continuing Review

10216, A Phase I/II Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer (Protocol Version Date 10/10/19)

III Continuing Review

9876, Phase 1b Study of HSP90 Inhibitor, AT13387 (onalespib) in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer. (Protocol Version Date 08/21/19)

IV Continuing Review

9930, A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL) (Protocol Version Date 06/21/19)

V Continuing Review

9950, A Phase I Study of M6620 (VX-970) in Combination with Cisplatin and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121) (Protocol Version Date 07/17/19)



FOR THE NATIONAL CANCER INSTITUTE

VI New Study - Initial Review

10388, A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (Protocol Version Date 12/20/19)

VII Amendment

9979, Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases (Protocol Version Date 01/07/20)
